---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-25-001428"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:51:32.454779+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant

## Summary
- Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.
- Approved grant of up to 5M shares for employees, advisors, directors, and consultants under performance metrics.
- Re-elected directors Ram Mukunda and James Moran as Class C directors until 2028.
- Ratified Manohar Chowdhry & Associates as independent auditor for fiscal 2026.
- Non-binding advisory vote set frequency of executive compensation votes every three years.

## SEC filing metadata
- accession: 0001185185-25-001428
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518525001428/0001185185-25-001428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518525001428/igc8k101025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-25-001428
- JSON: https://secwatch.observer/filing/0001185185-25-001428.json
- Plain text: https://secwatch.observer/filing/0001185185-25-001428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.